publication . Article . 2021

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

Benjamin Gaborit; Nicolas Degauque;
Open Access
  • Published: 09 Mar 2021 Journal: Trials, volume 22 (eissn: 1745-6215, Copyright policy)
  • Publisher: Springer Science and Business Media LLC
<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach. Polyclonal neutralizing antibodies offers many advantages such as providing immediate immunity, consequently blunting an early pro-inflammatory pathogenic endogenous antibody response and lack of drug-drug interactions.</jats:p> <jats:p>By providing immediate immunity and inhibiting entry into cells, neutralizing antibody treatment is of interest for patient with COVID-19-induced moderate pneumonia. Convalescent plasma to trea...
Persistent Identifiers
free text keywords: Medicine (miscellaneous), Pharmacology (medical)
Any information missing or wrong?Report an Issue